I5409

IRAK-1/4 Inhibitor I

≥98% (HPLC), solid

• Sinónimos: 1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole, N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole
• Fórmula empírica (notación de Hill): C₂₀H₂₁N₅O₄
• Número de CAS: 509093-47-4
• Peso molecular: 395.41
• MDL number: MFCD09752602
• UNSPSC Code: 51111800
• PubChem Substance ID: 329815384
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: solid
• color: off-white to light yellow
• solubility: DMSO: ≥5 mg/mL
• storage temp.: 2-8°C
• SMILES string: O=C(C1=CC([N+]([O-])=O)=CC=C1)NC2=NC3=C(N2CCN4CCOCC4)C=CC=C3
• InChI: 1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
• InChI key: QTCFYQHZJIIHBS-UHFFFAOYSA-N

Descripción

Application

IRAK-1/4 inhibitor I has been used in various studies to inhibit IRAK1 in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines.

Biochem/physiol Actions

IRAK-1/4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4). IC₅₀ values were 300 nM and 200 nM for IRAK-1 and -4, respectively, and >10,000 nM for a panel of 27 other kinases tested.

IRAK-1/4 Inhibitor I is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4, with IC₅₀ values of 300 nM and 200 nM for IRAK-1 and -4, respectively.

IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit inhibitory effects on the nuclear factor (NF)-κB signaling pathway.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• ppe: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges